Regeneron Pharma (REGN) PT Lowered to $320 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novartis' Beovu Label a Positive for Regeneron Pharma (REGN) - BMO
October 8, 2019 12:24 PM EDTBMO Capital analyst Matthew Luchini reiterated a Market Perform rating and $344.00 price target on Regeneron Pharma (NASDAQ: REGN), saying they were surprised by FDAs approval of Novartis Beovu (brolucizumab) in Wet AMD. However, they believe the label looks worse than expected, a... More
